Joseph Ciaffoni Net Worth

The estimated Net Worth of Joseph Ciaffoni is at least $27.3 Million dollars as of 21 December 2023. Mr. Ciaffoni owns over 4,357 units of Collegium Pharmaceutical Inc stock worth over $10,112,723 and over the last 8 years he sold COLL stock worth over $13,160,577. In addition, he makes $4,032,630 as President, Chief Executive Officer, and Director at Collegium Pharmaceutical Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Ciaffoni COLL stock SEC Form 4 insiders trading

Joseph has made over 18 trades of the Collegium Pharmaceutical Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 4,357 units of COLL stock worth $92,978 on 21 December 2023.

The largest trade he's ever made was selling 131,053 units of Collegium Pharmaceutical Inc stock on 1 December 2022 worth over $2,977,524. On average, Joseph trades about 17,277 units every 46 days since 2016. As of 21 December 2023 he still owns at least 279,357 units of Collegium Pharmaceutical Inc stock.

You can see the complete history of Mr. Ciaffoni stock trades at the bottom of the page.

Joseph Ciaffoni biography

Joseph J. Ciaffoni serves as President, Chief Executive Officer, Director of the Company. Mr. Ciaffoni has served as our President and Chief Executive Officer since July 2018, and prior to that, served as our Executive Vice President and Chief Operating Officer since May 2017. Prior to joining us, Mr. Ciaffoni served as President, U.S. Branded Pharmaceuticals of Endo International plc, a specialty pharmaceutical company, from August 2016 to December 2016. Before that, from April 2012 to August 2016, Mr. Ciaffoni held various positions of increasing responsibility at Biogen Idec, including Senior Vice President, Global Specialty Medicines Group, Senior Vice President, U.S. Commercial and Vice President, U.S. Neurology Field Operations and Marketing. Prior to joining Biogen Idec, Mr. Ciaffoni was Executive Vice President and Chief Operating Officer of Shionogi Inc. and President of Shionogi Pharmaceuticals from July 2008 to October 2010. Mr. Ciaffoni also previously served as Vice President, Sales for Schering-Plough (now Merck) from May 2004 to June 2008, where he was responsible for the cholesterol franchise, and has held several commercial leadership roles at Sanofi-Synthelabo (now Sanofi) from January 2002 to April 2004 and Novartis from January 1994 to December 2001. Mr. Ciaffoni received a B.A. in Communications in 1993 and an M.B.A. in 2000, both from Rutgers, The State University of New Jersey.

What is the salary of Joseph Ciaffoni?

As the President, Chief Executive Officer, and Director of Collegium Pharmaceutical Inc, the total compensation of Joseph Ciaffoni at Collegium Pharmaceutical Inc is $4,032,630. There are no executives at Collegium Pharmaceutical Inc getting paid more.

How old is Joseph Ciaffoni?

Joseph Ciaffoni is 49, he's been the President, Chief Executive Officer, and Director of Collegium Pharmaceutical Inc since 2018. There are 13 older and 5 younger executives at Collegium Pharmaceutical Inc. The oldest executive at Collegium Pharmaceutical Inc is John Fallon, 72, who is the Independent Director.

What's Joseph Ciaffoni's mailing address?

Joseph's mailing address filed with the SEC is C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072.

Insiders trading at Collegium Pharmaceutical Inc

Over the last 9 years, insiders at Collegium Pharmaceutical Inc have traded over $80,399,308 worth of Collegium Pharmaceutical Inc stock and bought 1,112,375 units worth $13,316,951 . The most active insiders traders include Group Holdings (Sbs) Adviso..., John Gordon Freund, and David Hirsch. On average, Collegium Pharmaceutical Inc executives and independent directors trade stock every 35 days with the average trade being worth of $2,130,406. The most recent stock trade was executed by Shirley R. Kuhlmann on 5 September 2024, trading 20,225 units of COLL stock currently worth $773,809.

What does Collegium Pharmaceutical Inc do?

collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex

Complete history of Mr. Ciaffoni stock trades at Collegium Pharmaceutical Inc and Endo International plc

Collegium Pharmaceutical Inc executives and stock owners

Collegium Pharmaceutical Inc executives and other stock owners filed with the SEC include:

• Joseph Ciaffoni,
  President, Chief Executive Officer, Director
• Scott Dreyer,
  Executive Vice President, Chief Commercial Officer
• Richard Malamut,
  Executive Vice President and Chief Medical Officer
• Paul Brannelly,
  Chief Financial Officer, Executive Vice President
• Shirley Kuhlmann,
  Executive Vice President, General Counsel, Secretary
• Alison Fleming,
  Executive Vice President, Chief Technology Officer
• Joseph J. Ciaffoni,
  Pres, CEO & Director
• Shirley R. Kuhlmann,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Richard Malamut,
  Exec. VP & Chief Medical Officer
• Michael Heffernan,
  Chairman of the Board
• Gino Santini,
  Lead Independent Director
• Garen Bohlin,
  Independent Director
• John Fallon,
  Independent Director
• Theodore Schroeder,
  Independent Director
• John Freund,
  Independent Director
• Gwen Melincoff,
  Independent Director
• Michael Thomas Heffernan B.S. Pharm, R.Ph.,
  Co-Founder & Chairman
• Michael Thomas Heffernan,
  Co-Founder & Chairman
• Rita Balice-Gordon,
  Director
• Scott Sudduth,
  Head of Technical Operations
• Marlo Manning,
  Head of HR
• Scott Dreyer,
  Exec. VP & Chief Commercial Officer
• Colleen Tupper,
  Exec. VP & CFO
• Jack Maroney,
  VP of Sales
• Bart J. Dunn,
  Exec. VP of Strategy & Corp. Devel.
• Alex Dasalla,
  Head of Investor Relations
• Barry S Duke,
  See remarks
• Eran Nadav,
  Director
• David Hirsch,
  Director
• Yasunori Kaneko,
  10% owner
• Venture Partners V Lp Skyli...,
  
• Capital Partners, Llc Tamme...,
  
• Thomas B Smith,
  EVP and Chief Medical Officer
• Colleen Tupper,
  EVP & Chief Financial Officer
• Patrick J Heron,
  Director
• Capital Partners, Llc Longi...,
  
• Healthcare Vi, L.P.Fhm Vi, ...,
  
• Group Holdings (Sbs) Adviso...,
  
• Venture Partners V Lp Skyli...,
  
• Neil F. Mc Farlane,
  Director